OBJECTIVES: The goal of this paper was to determine whether assessment of left ventricular ejection fraction (LVEF) enhances prediction of new-onset heart failure (HF) and cardiovascular mortality over and above N-terminal pro-B-type natriuretic peptide (NT-proBNP) level in older adults. BACKGROUND: Elevated NT-proBNP levels are common in older adults and are associated with increased risk of HF. METHODS: NT-proBNP and LVEF were measured in 4,137 older adults free of HF. Repeat measures of NT-proBNP were performed 2 to 3 years later and echocardiography was repeated 5 years later (n = 2,375), with a median follow-up of 10.7 years. The addition of an abnormal (<55%) LVEF (n = 317 [7.7%]) to initially elevated or rising NT-proBNP levels was evaluated to determine risk of HF or cardiovascular mortality. Changes in NT-proBNP levels were also assessed for estimating the risk of conversion from a normal to abnormal LVEF. RESULTS: For participants with a low baseline NT-proBNP level (<190 pg/ml; n = 2,918), addition of an abnormal LVEF did not improve the estimation of risk of HF and identified a moderate increase in adjusted risk for cardiovascular mortality (hazard ratio: 1.69 [95% confidence interval: 1.22 to 2.31]). Among those whose NT-proBNP subsequently increased ≥25% to ≥190 pg/ml, an abnormal LVEF was likewise associated with an increased risk of cardiovascular mortality but not HF. Participants with an initially high NT-proBNP level (≥190 pg/ml) were at greater risk overall for both outcomes, and those with an abnormal LVEF were at the highest risk. However, an abnormal LVEF did not improve model classification or risk stratification for either endpoint when added to demographic factors and change in NT-proBNP. An initially elevated NT-proBNP or rising level was associated with an increased risk of developing an abnormal LVEF. CONCLUSIONS: Assessment of LVEF in HF-free older adults based on NT-proBNP levels should be considered on an individual basis, as such assessments do not routinely improve prognostication.
OBJECTIVES: The goal of this paper was to determine whether assessment of left ventricular ejection fraction (LVEF) enhances prediction of new-onset heart failure (HF) and cardiovascular mortality over and above N-terminal pro-B-type natriuretic peptide (NT-proBNP) level in older adults. BACKGROUND: Elevated NT-proBNP levels are common in older adults and are associated with increased risk of HF. METHODS: NT-proBNP and LVEF were measured in 4,137 older adults free of HF. Repeat measures of NT-proBNP were performed 2 to 3 years later and echocardiography was repeated 5 years later (n = 2,375), with a median follow-up of 10.7 years. The addition of an abnormal (<55%) LVEF (n = 317 [7.7%]) to initially elevated or rising NT-proBNP levels was evaluated to determine risk of HF or cardiovascular mortality. Changes in NT-proBNP levels were also assessed for estimating the risk of conversion from a normal to abnormal LVEF. RESULTS: For participants with a low baseline NT-proBNP level (<190 pg/ml; n = 2,918), addition of an abnormal LVEF did not improve the estimation of risk of HF and identified a moderate increase in adjusted risk for cardiovascular mortality (hazard ratio: 1.69 [95% confidence interval: 1.22 to 2.31]). Among those whose NT-proBNP subsequently increased ≥25% to ≥190 pg/ml, an abnormal LVEF was likewise associated with an increased risk of cardiovascular mortality but not HF. Participants with an initially high NT-proBNP level (≥190 pg/ml) were at greater risk overall for both outcomes, and those with an abnormal LVEF were at the highest risk. However, an abnormal LVEF did not improve model classification or risk stratification for either endpoint when added to demographic factors and change in NT-proBNP. An initially elevated NT-proBNP or rising level was associated with an increased risk of developing an abnormal LVEF. CONCLUSIONS: Assessment of LVEF in HF-free older adults based on NT-proBNP levels should be considered on an individual basis, as such assessments do not routinely improve prognostication.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: C D Furberg; T A Manolio; B M Psaty; D E Bild; N O Borhani; A Newman; B Tabatznik; P M Rautaharju Journal: Am J Cardiol Date: 1992-05-15 Impact factor: 2.778
Authors: A Mark Richards; M Gary Nicholls; Eric A Espiner; John G Lainchbury; Richard W Troughton; John Elliott; Christopher Frampton; John Turner; Ian G Crozier; Timothy G Yandle Journal: Circulation Date: 2003-05-27 Impact factor: 29.690
Authors: B M Psaty; L H Kuller; D Bild; G L Burke; S J Kittner; M Mittelmark; T R Price; P M Rautaharju; J Robbins Journal: Ann Epidemiol Date: 1995-07 Impact factor: 3.797
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: J M Gardin; N D Wong; W Bommer; H S Klopfenstein; V E Smith; B Tabatznik; D Siscovick; S Lobodzinski; H Anton-Culver; T A Manolio Journal: J Am Soc Echocardiogr Date: 1992 Jan-Feb Impact factor: 5.251
Authors: Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett Journal: Circulation Date: 2004-06-07 Impact factor: 29.690
Authors: Paul A Heidenreich; Matthew A Gubens; Gregg C Fonarow; Marvin A Konstam; Lynne W Stevenson; Paul G Shekelle Journal: J Am Coll Cardiol Date: 2004-03-17 Impact factor: 24.094
Authors: J M Gardin; D Siscovick; H Anton-Culver; J C Lynch; V E Smith; H S Klopfenstein; W J Bommer; L Fried; D O'Leary; T A Manolio Journal: Circulation Date: 1995-03-15 Impact factor: 29.690
Authors: Christopher R deFilippi; James A de Lemos; Andrew T Tkaczuk; Robert H Christenson; Mercedes R Carnethon; David S Siscovick; John S Gottdiener; Stephen L Seliger Journal: J Am Coll Cardiol Date: 2012-11-14 Impact factor: 24.094
Authors: Bruce M Psaty; Joseph A Delaney; Alice M Arnold; Lesley H Curtis; Annette L Fitzpatrick; Susan R Heckbert; Barbara McKnight; Diane Ives; John S Gottdiener; Lewis H Kuller; W T Longstreth Journal: Circulation Date: 2015-11-04 Impact factor: 29.690
Authors: Siti Nur Baait Biniti Mohd Sokran; Vikram Mohan; Kamaria Kamaruddin; Mohd Daud Sulaiman; Yahya Awang; Ida Rosmini Binti Othman; Smiley Jesu Priya Victor Journal: Iran J Med Sci Date: 2015-07
Authors: Lotte Jacobs; Lutgarde Thijs; Yu Jin; Faiez Zannad; Alexandre Mebazaa; Philippe Rouet; Florence Pinet; Christophe Bauters; Burkert Pieske; Andreas Tomaschitz; Mamas Mamas; Javier Diez; Kenneth McDonald; John G F Cleland; Hans-Peter Brunner-La Rocca; Stephane Heymans; Roberto Latini; Serge Masson; Peter Sever; Christian Delles; Stuart Pocock; Timothy Collier; Tatiana Kuznetsova; Jan A Staessen Journal: J Biomed Res Date: 2014-07-31
Authors: Lotte Jacobs; Ljupcho Efremov; João Pedro Ferreira; Lutgarde Thijs; Wen-Yi Yang; Zhen-Yu Zhang; Roberto Latini; Serge Masson; Nera Agabiti; Peter Sever; Christian Delles; Naveed Sattar; Javed Butler; John G F Cleland; Tatiana Kuznetsova; Jan A Staessen; Faiez Zannad Journal: J Am Heart Assoc Date: 2017-05-02 Impact factor: 5.501